PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
Phase 2
Terminated
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 219
- Registration Number
- NCT00372996
- Locations
- π¦π·
Instituto de Investigaciones Clinicas, Rosario, Santa Fe, Argentina
π§πͺUZ Gasthuisberg, Medische Oncologie, Leuven, Belgium
π¦π·Centro Oncologico Rosario, Rosario, Santa Fe, Argentina
An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit Smoking
Phase 3
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 334
- Registration Number
- NCT00371813
- Locations
- πΉπ
Pfizer Investigational Site, Chiang Mai, Thailand
Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2007-02-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 345
- Registration Number
- NCT00370565
- Locations
- π¨π¦
Pfizer Investigational Site, Laval, Quebec, Canada
Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity
Phase 2
Terminated
- Conditions
- Obesity
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT00367783
- Locations
- πΊπΈ
Pfizer Investigational Site, San Antonio, Texas, United States
Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2008-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 397
- Registration Number
- NCT00367653
- Locations
- πΏπ²
Pfizer Investigational Site, Ndola, Zambia
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2008-01-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00367445
- Locations
- πΊπΈ
Pfizer Investigational Site, Chula Vista, California, United States
Zmax Compared to Augmentin in Sinusitis
Phase 4
Completed
- Conditions
- Sinusitis
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2010-03-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 762
- Registration Number
- NCT00367120
A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Forteo
- First Posted Date
- 2006-08-18
- Last Posted Date
- 2009-03-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00365924
- Locations
- π¦π·
Pfizer Investigational Site, Capital Federal - Buenos Aires, Argentina
Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B
Phase 3
Completed
- Conditions
- Hemophilia B
- Interventions
- Drug: Recombinant Coagulation Factor IX (BeneFIX)
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT00364182
- Locations
- πͺπΈ
Pfizer Investigational Site, Sevilla, Spain
A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases
Phase 3
Completed
- Conditions
- Acute Bronchitis
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64
- Registration Number
- NCT00360464
- Locations
- π―π΅
Pfizer Investigational Site, Yonezawa, Yamagata, Japan
Β© Copyright 2025. All Rights Reserved by MedPath